Home » Newsletters » BioWorld

BioWorld

April 8, 1994

View Archived Issues

HYBRIDON OK'D FOR GEM 91 TRIAL

APPOINTMENTS AND ADVANCEMENTS

TARGETED GENETICS LICENSES AAV TECHNOLOGIES

AGENNIX PRODUCING COMMERCIALLY VIABLE LACTOFERRIN

SEPRACOR SPINOFF NETS $13M IN IPO

POLICY REVIEW CONTINUES ON GENETICALLY-ENGINEERED FOOD

TEXAS BIOTECH INTENDS TO BUY IPI

VIVUS IPO NETS $28M

WHY MEMORY LOSS IN ALZHEIMER'S PRECEDES TELLTALE AMYLOID PLAQUES

FDA APPROVES THALIDOMIDE TRIALS

Today's news in brief
BioWorld
BioWorld briefs for Jan. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 17, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Abbvie and Simcere enter a $1B T-cell engager deal
BioWorld Asia
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.